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Apolipoprotein A-I (apoA-I) is deposited as amyloid within various major organs in hereditary apoA-
I amyloidosis, and in arterial plaques associated with atherosclerosis. We have identiﬁed a tryptic
fragment of apoA-I, apoA-I46–59, that retains the ability to form amyloid-like ﬁbrils with cross-b
structure. ApoA-I46–59 corresponds closely to a conformationally extended segment in the crystal
structure of apoA-ID(185–243) and is located in the N-terminal region of apoA-I, which accumulates
in hereditary apoA-I amyloidosis. Our results provide direct experimental evidence that this region
of apoA-I is amyloidogenic and integral to initiation and propagation of amyloid formation by the
protein.
Structured summary of protein interactions:
apoA-I and apoA-I bind by transmission electron microscopy (View Interaction: 1, 2, 3)
apoA-I and apoA-I bind by ﬂuorescence technology (View Interaction: 1, 2)
apoA-I and apoA-I bind by X-ray ﬁber diffraction (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Amyloid deposits composed of apoA-I are also commonly foundApolipoprotein A-I (apoA-I) is the major structural protein com-
ponent of plasma high density lipoproteins (HDL) and belongs to
the family of exchangeable apolipoproteins. ApoA-I plays a central
role in reverse cholesterol transport, and high plasma levels of both
HDL and apoA-I represent strong negative predictors of the inci-
dence of cardiovascular events [1,2].
ApoA-I is deposited as amyloid in various tissues in association
with hereditary and non-hereditary apoA-I amyloidoses. To date,
19 speciﬁc mutations in the apoA-I sequence have been identiﬁed
that lead to apoA-I amyloid deposition in various major organs
including the heart, liver and kidneys [3,4]. In general, apoA-I amy-
loid extracted from patients with hereditary apoA-I amyloidosis
consists of the N-terminal 80-100 residues; however, the processes
underlying the formation of these fragments have not been
deﬁned.chemical Societies. Published by E
igh density lipoprotein; RCT,
LC, high performance liquid
ission electron microscopy
Grifﬁn).
olecular Medicine, Friedrich-
ngen, Germany.in atherosclerotic plaques, in the non-hereditary form of apoA-I
amyloidosis [5]. This arterial amyloid forms from non-variant
apoA-I, indicating that mutations in the protein are not essential
for its conversion into amyloid. Our recent work showed that oxi-
dative modiﬁcation of apoA-I methionine residues leads to amyloid
formation by the native, intact protein [6]. However, the nature of
the arterial form of apoA-I amyloid, and its pathological signiﬁ-
cance, are currently poorly understood.
ApoA-I exists in circulation as both HDL-bound and lipid-poor/
lipid-free forms. The lipid-poor/lipid-free form of apoA-I accounts
for less than 10% of total circulating apoA-I and is thought to be
the primary acceptor of cholesterol [1]. In vitro, lipid-free apoA-I
exists in solution as a dynamic equilibrium between monomer
and higher order oligomers [6,7], and possesses a high degree of
conformational plasticity [8]. It is likely that the inherent structural
instability of apoA-I contributes to its propensity to misfold and
form amyloid [9].
It is increasingly clear that many amyloidogenic proteins con-
tain a single, short peptide sequence that is responsible for the spe-
ciﬁc aggregation of the protein into amyloid ﬁbrils [10]. In many
cases these isolated peptide sequences are able to form amyloid-
like ﬁbrils in their own right, and are frequently used as models
for amyloid formation by full-length proteins [11–13]. To date,
the core amyloidogenic segment of the apoA-I sequence has not
been systematically characterised.lsevier B.V. All rights reserved.
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apoA-I forms ﬁbrils with the major deﬁning properties of amyloid.
Our results provide direct experimental evidence that this region is
responsible for the initiation and propagation of apoA-I amyloid
formation in the apoA-I amyloidoses.
2. Materials and methods
2.1. Proteolysis
ApoA-I (1.6 mg, in 1 ml 100 mM sodium phosphate, pH 7.4, 0.1%
w/v NaN3) was digested with trypsin (5 lg) or endoproteinase Glu-
C (20 lg) in separate experiments. Digestion was judged to be
complete when full-length apoA-I and proteolyic fragments were
no longer resolvable on 16% Tris-tricine SDS-PAGE. The proteolysed
peptide solutions were then incubated at 37 C using a Thermom-
ixer Comfort orbital shaker (Eppendorf) with shaking at 600 rpm.
Formation of aggregates was monitored by thioﬂavin T (ThT) ﬂuo-
rescence as described below (Thioﬂavin T ﬂuorescence assays).
2.2. Peptide aggregate harvesting
Four hundred microlitres of the tryptic peptide aggregate sus-
pension was pelleted by centrifugation for 30 min at 100,000 rpm
and 20 C using a TLA-100 rotor in an OptimaMax Ultracentrifuge
(Beckman Coulter). The supernatant was collected, and the pellet
was resuspended in an equal volume of 100 mM sodium phos-
phate, pH 7.4. The resuspended aggregates were further centri-
fuged twice as above, to remove any residual supernatant
components. The ﬁnal pellet was resuspended in an equal volume
of 100 mM sodium phosphate buffer, pH 7.4.
2.3. High performance liquid chromatography and mass spectrometry
The pellet fraction harvested from the aged tryptic digest of
apoA-I was solubilised and applied to a C4 reversed-phase column.
The column was eluted using a linear gradient of 95% acetonitrile,
0.1% triﬂuoroacetic acid. Elution of tryptic fragments was moni-
tored by absorption at 214 nm, and eluted peaks were collected
manually. Mass spectrometry was performed on an Agilent Quad-
rupole time of ﬂight instrument equipped with an ESI source. Mass
spectral data were analysed using the program Mass Spectrum
Analyser (Agilent).
2.4. Peptide synthesis
ApoA-I46–59 (LLDNWDSVTSTFSK), apoA-I49–59 (NWDSVTSTFSK),
and ApoA-I52–59 (SVTSTFSK) peptides were synthesised manually
by Bio21 Peptide Technology (Vic., Australia) with free amine
and free carboxylic acid termini using Fmoc-solid phase peptide
synthesis, essentially as previously described [14]. The purity of
all peptides was assessed to be >95% by reversed-phase HPLC
and mass spectrometry using an LC ESI-TOF mass spectrometer
(Agilent). Stocks of the peptides (30 mg/ml) were stored in 5 M
guanidine hydrochloride, 10 mM Tris.HCl, pH 8.0 at 20 C.
2.5. Thioﬂavin T ﬂuorescence assays
Fibril formation by the synthetic peptides was initiated by
diluting the peptide stocks (as above) in 100 mM sodium phos-
phate, pH 7.4, 0.1% w/v NaN3 at room temperature without shak-
ing. At deﬁned time points, 20 ll aliquots of the peptide samples
were added to 230 ll of 8.8 lM ThT in 100 mM sodium phosphate,
pH 7.4, in a 96 well plate (ﬁnal ThT concentration, 8 lM). Fluores-
cence measurements were conducted in duplicate using an fmaxﬂuorescence plate reader (Molecular Devices) equipped with exci-
tation and emission ﬁlters of 444 nm and 485 nm, respectively.
2.6. Transmission electron microscopy
Peptide samples were diluted to 0.1 mg/ml and applied to
glow-discharged, carbon coated 300-mesh copper grids (ProSci-
Tech) for 1 min. Grids were negatively stained with 2% (w/v) potas-
sium phosphotungstate, pH 6.8, or 1.5% (w/v) aqueous uranyl
acetate, blotted, and air dried. Samples were examined at the
Bio21 Electron Microscopy Unit (Vic., Australia) using a FEI Tecnai
TF30 Transmission Electron Microscope. Images were recorded
using a Gatan US1000 2k  2k CCD camera.
2.7. Circular dichroism spectroscopy
Far UV circular dichrosim (CD) spectra were recorded for apoA-
I46–59 (185 lM, in 100 mM sodium phosphate, pH 7.4) after incuba-
tion for 0, 2, and 8 h using an Aviv 410SF CD spectrometer. Spectra
were acquired between 200 and 250 nm at 20 C, using a 1 mm
path-length quartz cuvette, 0.5 nm step size, and 8 s averaging.
Raw spectra were corrected for buffer contribution and converted
to mean residue ellipticity.
2.8. Tryptophan ﬂuorescence
Tryptophan ﬂuorescence measurements were made for freshly
prepared (unaggregated) and ﬁbrillar apoA-I46–59 (185 lM, in
100 mM sodium phosphate, pH 7.4) using a Cary Eclipse ﬂuorime-
ter (Varian) at 20 C. Emission spectra were recorded between 300
and 500 nm using an excitation wavelength of 295 nm.
2.9. X-ray ﬁbre diffraction
ApoA-I46–59 ﬁbrils were prepared at a peptide concentration of
185 lM and allowed to mature for several days. Fibrils were pel-
leted by centrifugation at 14,000 rpm for 10 min, followed by
resuspension in distilled water. Centrifugation and resuspension
were repeated three times to remove buffer salts. Finally, the ﬁbril
pellet was resuspended in a small volume of distilled water, to a
concentration of approximately 10 mg/ml. Fibrils were aligned
using a modiﬁcation of the stretch frame method as described pre-
viously [15]. X-ray diffraction images were acquired at the Austra-
lian Synchrotron MX1 beam-line operating at 13.0 keV
(k = 0.954 Å). The sample-to-detector distance was 200 mm, and
the exposure time was 6 s. Background air scattering obtained un-
der identical conditions with no sample in the beam was sub-
tracted from raw diffraction images prior to analysis.
3. Results
3.1. A tryptic peptide fragment of apoA-I aggregates to form ﬁbrils
In an effort to identify the amyloidogenic region or regions of
apoA-I, the protein was completely digested using trypsin or endo-
proteinase Glu-C in two separate proteolysis experiments. Due to
the different cleavage speciﬁcities of trypsin (carboxyl side of basic
residues) and Glu-C (carboxyl side of acidic residues) the two di-
gests resulted in peptides of distinct but overlapping apoA-I se-
quence ranges, improving the possibility of identifying intact
amyloidogenic peptides. These crude apoA-I peptide mixtures
were incubated at pH 7.4 and 37 C with shaking for a number of
weeks. During this period the samples were analysed for the devel-
opment of thioﬂavin T (ThT) ﬂuorescence, which is commonly used
for the detection of amyloid in vitro. The results showed increasing
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with an increase in turbidity, indicating aggregation of the peptide
components.
The aggregates were pelleted by ultracentrifugation and care-
fully separated from the supernatant. Inspection of the resus-
pended pellet fraction by transmission electron microscopy
(TEM) revealed that this was made up of well deﬁned, regular
ﬁbrillar structures of around 20 nmwide and up to several microns
in length (Fig. 1).
To identify the peptide, or peptides, comprising these ﬁbrils, the
pellet fraction from the trypsin digest was subjected to reversed-
phase HPLC, followed by mass spectrometry. HPLC analysis
showed a single major eluting peak (Supplementary Figure S1).
Mass spectrometry of this fraction provided a single mass of
1612.8 Da, corresponding to the mass of the tryptic peptide com-
prising residues 46–59 of apoA-I (apoA-I46–59; LLDNWDSVTSTFSK).
Together these results show that the observed ﬁbrils are composed
of a single speciﬁc peptide.
3.2. Synthetic apoA-I46–59 forms ﬁbrils with an amyloid cross-b
structure
To conﬁrm that this peptide was able to form amyloid ﬁbrils in
isolation, the apoA-I46–59 peptide was synthesised. Analysis of the
aggregation of synthetic apoA-I46–59 was carried out using ThT
ﬂuorescence at pH 7.4. The time course of development of ThT
ﬂuorescence in this sample was characterised by a short lag-phase
of around 15 min followed by a sharp increase in ﬂuorescence,
with aggregation complete after around 4 h (Fig. 2A). Tryptophan
ﬂuorescence emission data collected for apoA-I46–59 before and
after incubation were consistent with aggregation of the peptide
(Supplementary Figure S2) and far UV CD spectra indicated struc-
tural rearrangement of the peptide during the process of aggrega-
tion (Supplementary Figure S3). TEM of the aggregated apoA-I46–59
peptide sample revealed ordered, ﬁbrillar structures (Fig. 2B) sim-
ilar to those found in the crude tryptic digest. These ﬁbrils dis-
played a regular twisted-ribbon, amyloid-like morphology with
width of 25–30 nm at their widest and a well deﬁned helical twist
with approximate period of 180–210 nm.
Amyloid ﬁbrils contain a common structure in which two or
more large b-sheets are formed from repeating b-strands, and this
structural conﬁguration produces a signature cross-b X-ray ﬁbre
diffraction pattern [16]. To probe the molecular structure of the
apoA-I46–59 ﬁbrils, X-ray diffraction data were collected from sam-
ples of partially aligned ﬁbrils using the MX1 beam-line of theFig. 1. Transmission electron microscope image of ﬁbrils harvested by centrifugal
pelleting of aggregates from the crude tryptic digest. Scale bar represents 100 nm.
Fig. 2. Fibril formation by synthetic peptides. (A) ThT ﬂuorescence monitored over
time for apoA-I46–59 (185 lM; d), apoA-I49–59 (235 lM; s), apoA-I52–59 (585 lM;
.). Error bars represent the standard error of the mean of duplicate measurements.
(B) Transmission electron microscope image of ﬁbrils formed from synthetic apoA-
I46–59. Scale bar represents 100 nm. (C) Cross-b X-ray diffraction pattern from
aligned, semi-hydrated apoA-I46–59 ﬁbrils. The spacing of the major meridional
reﬂection is indicted on the horizontal axis, and the approximate spacings of the
equatorial reﬂections are indicated on the vertical axis. Partial smearing of
diffraction peaks into rings may indicate incomplete alignment of ﬁbrils.Australian Synchrotron. The diffraction images (Fig. 2C) revealed
a classical cross-b diffraction pattern with orthogonal reﬂections.
The sharp meridional peak at a spacing of 4.75 Å indicates the
distance between hydrogen bonded b-strands in the direction of
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11.5 Å most likely represents the average spacing between b-
sheets in the ﬁbril cross section [16]. The presence of multiple
peaks in the equatorial axis may indicate more complex cross sec-
tional structure such as the packing of three or more b-sheets, or
the complex arrangement of a number of protoﬁlaments, each con-
sisting of two or more b-sheets. The absence of reﬂections expected
for ordered a-helical structure (around 1.5 and 5 Å) suggests that
the presence of stable helical structure within the ﬁbrils is unlikely
[16]. These ﬁbre diffraction data indicate that the ﬁbrils formed by
apoA-I46–59 contain the cross-b structure that deﬁnes amyloid
ﬁbrils.
3.3. Truncated apoA-I46–59 peptides show altered capacity for ﬁbril
formation
To further investigate the amyloidogenic properties of the
apoA-I46–59 peptide sequence, two truncated peptides were syn-
thesised, apoA-I49–59 (NWDSVTSTFSK) and apoA-I52–59 (SVTSTFSK).
These truncations correspond to points of cleavage by endopro-
teinase Glu-C within the apoA-I46–59 sequence. Incubation of
apoA-I49–59 at a concentration of 235 lM resulted in a time depen-
dent increase in ThT ﬂuorescence; however, the onset of aggrega-
tion was slower than that of apoA-I46–59, with a lag phase of
several hours (Fig. 2A). The ability of apoA-I49–59 to form ﬁbrils
was conﬁrmed by TEM, which revealed ordered amyloid-like ﬁbrils
(Supplementary Figure S4).
In contrast, ThT ﬂuorescence remained low and constant during
incubation of apoA-I52–59 at a concentration of 585 lM (Fig. 2A),
and incubation of the peptide at elevated concentrations (up to
1 mM) for extended incubation periods of several weeks showed
no development of aggregates by TEM. Taken together these re-
sults indicate that apoA-I52–59 was resistant to aggregation under
these conditions.4. Discussion
We have shown that the peptide comprising residues 46–59 of
apoA-I aggregates to form amyloid-like ﬁbrils that bind the amy-
loid diagnostic dye, ThT, and contain cross-b structure. These re-
sults show that apoA-I46–59 contains all the sequence
determinants necessary for amyloid formation, and suggest that
this segment of the protein is responsible for the self-recognition
and aggregation of apoA-I into amyloid ﬁbrils. This assertion is
supported by the fact that residues 46–59 are situated within the
central part of the N-terminal 80–100 residue fragments of apoA-
I that comprise the amyloid deposits of patients suffering from
hereditary apoA-I amyloidosis.
Truncation of the apoA-I46–59 peptide from the N-terminus
showed that residues 46–48 were not critical for ﬁbril formation,
with apoA-I49–59 able to form amyloid-like ﬁbrils. Conversely, the
resistance of apoA-I52–59 to ﬁbril formation suggests that residues
49–51 play an essential role in aggregation. This requirement of
residues 49–51 for ﬁbril formation may explain why the endopro-
teinase Glu-C cleavage product spanning residues 52–62 of apoA-I
did not aggregate. Analysis of the full apoA-I sequence using the
Waltz algorithm, for prediction of amyloidogenic regions of protein
sequences [17], identiﬁed residues 53–58 (VTSTFS) as the most
highly amyloidogenic region of apoA-I. Nevertheless, the results
presented here show that this sequence is not the sole requirement
for aggregation and that adjacent regions of the protein play a sig-
niﬁcant role in ﬁbril formation. The importance of sequences ﬂank-
ing the core hydrophobic regions in the process of amyloid
formation has previously been demonstrated for the yeast prion,
sup35 [18], and Ab [19].The crystal structure of a C-terminal truncation of apoA-I, apoA-
ID(185–243), has recently been solved [20] and analysed in an
effort to better understand the processes underlying amyloid for-
mation by the mutant forms of apoA-I [3]. One of the key ﬁndings
of this analysis was the identiﬁcation of a segment of the protein,
residues 44–55, that is present in an extended conformation within
the otherwise largely a-helical structure [3]. The peptide identiﬁed
independently in the present report corresponds very closely to
this conformationally extended segment, providing direct experi-
mental evidence that this region is amyloidogenic. Thus, exposure
of this relatively unstructured segment is likely to be intimately
involved in the initiation and propagation of apoA-I aggregation
to form b-sheet rich amyloid ﬁbrils in apoA-I amyloidosis.
Our previous work showed that oxidation of the methionine
residues of apoA-I caused the destabilisation of the tertiary and
quaternary structure of the protein, ultimately leading to amyloid
formation by the full-length protein [6]. The present data suggest
that this breakdown in conformational stability of apoA-I results
in increased exposure of residues 46–59 of the protein, initiating
aggregation and conversion into amyloid. Further studies into the
effects of the hereditary amyloidogenic mutations on the stability
and processing of apoA-I will elucidate the mechanisms that
lead to the exposure and aggregation of this sequence in these
diseases.
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